IPCALAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.9
| Stock Code | IPCALAB | Market Cap | 39,963 Cr. | Current Price | 1,573 ₹ | High / Low | 1,679 ₹ |
| Stock P/E | 39.8 | Book Value | 292 ₹ | Dividend Yield | 0.25 % | ROCE | 17.3 % |
| ROE | 12.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,542 ₹ | DMA 200 | 1,471 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.14 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 51.5 | MACD | 21.0 | Volume | 78,026 | Avg Vol 1Wk | 1,60,046 |
| Low price | 1,252 ₹ | High price | 1,679 ₹ | PEG Ratio | -31.1 | Debt to equity | 0.11 |
| 52w Index | 75.2 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 31.6 |
📈 Optimal Buy Price: 1,560 – 1,575 ₹
💰 Profit-Taking Levels: 1,600 ₹ / 1,625 ₹
🛑 Stop-Loss Zone: 1,540 ₹
⏳ Exit Guidance: If already holding, consider exiting near 1,600–1,610 ₹ if momentum slows. Exit below 1,540 ₹ if bearish volume spikes or RSI dips under 48.
✅ Positive
- ROCE (17.3%) and ROE (12.4%) show moderate efficiency.
- Price trading above DMA 50 (1,542 ₹) and DMA 200 (1,471 ₹), confirming short-term strength.
- MACD at 21.0 indicates bullish crossover momentum.
- Quarterly profit variation (+13.4%) shows earnings consistency.
- Low debt-to-equity ratio (0.11) ensures financial stability.
⚠️ Limitation
- EPS at 31.7 ₹ is modest compared to valuation.
- High P/E (39.8) vs industry PE (31.6) suggests premium valuation.
- PEG ratio (-31.1) reflects weak earnings growth relative to valuation.
- Dividend yield at 0.25% is low, limiting passive income.
- Volume (78k) below weekly average (160k), showing reduced intraday participation.
📉 Company Negative News
- PAT remained flat (₹305 Cr → ₹303 Cr), showing stagnation in earnings growth.
- Weak PEG ratio highlights growth concerns.
📊 Company Positive News
- Institutional confidence stable with slight increases in FII (+0.01%) and DII (+0.14%) holdings.
- Strong 52-week index gain of 75.2% highlights price performance.
🏭 Industry
- Pharma sector trades at lower PE (31.6), but IPCALAB commands a premium due to brand strength.
- Industry outlook remains positive with demand for healthcare and pharma products supporting valuations.
📌 Conclusion
IPCALAB shows moderate fundamentals with decent ROE/ROCE and strong price performance, but high valuation multiples and weak PEG ratio limit attractiveness for intraday trading. Entry near 1,560–1,575 ₹ with exits around 1,600–1,625 ₹ is suitable for cautious trades. Strict stop-loss discipline at 1,540 ₹ is essential due to reduced volume and premium valuation.
Would you like me to extend this into a sector overlay with pharma peers like CIPLA, Sun Pharma, and Dr. Reddy’s, or prepare a swing trade analysis for medium-term positioning?